نتایج جستجو برای: jak2 v617f

تعداد نتایج: 4704  

2008
Naoki Mori Kentaro Yoshinaga Makiko Tada Yanhua Wang Masayuki Shiseki Toshiko Motoji

A unique mutation of the JAK2 gene, V617F, has recently been identified in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis. To determine the relevance of this mutation in other types of hematological neoplasms in Japan, we performed allele-specific polymerase chain reaction analysis on the JAK2 gene. The V617F mutation was detected in one out of 130 myeloi...

2014
Mario Cazzola Robert Kralovics

Our knowledge of the genetic basis of these disorders began in 2005, when a unique base substitution in JAK2, the gene encoding Janus kinase 2,was found inpatientswith polycythemia vera, essential thrombocythemia, and primary myelofibrosis. The background of our investigations was the previous finding that copy-neutral loss of heterozygosity of chromosome 9p (9pLOH) is the most common chromosom...

2016
KATIA BORGIA BARBOSA PAGNANO MÁRCIA TORRESAN DELAMAIN MARIANA MUNARI MAGNUS JOSÉ VASSALLO CARMINO ANTONIO DE SOUZA DAIANE DE ALMEIDA IRENE LORAND-METZE

The association of chronic myeloid leukemia (CML) with other myeloproliferative neoplasms (MPNs), in particular with the V617F mutation in the Janus kinase 2 (JAK2) gene, is very uncommon, and there are only a few cases reported in the literature. In the present study, the case of a 73-year-old man with CML and persistent thrombocytosis, is reported. The patient achieved a complete cytogenetic ...

Journal: :American journal of clinical pathology 2010
Meredith A Lakey Animesh Pardanani James D Hoyer Phuong L Nguyen Terra L Lasho Ayalew Tefferi Curtis A Hanson

The diagnosis of polycythemia vera (PV) requires the integration of clinical and laboratory findings, bone marrow morphologic features, and JAK2 analysis. JAK2(V617F) (exon 14) mutation is found in 95% of PV cases. Functionally similar mutations in JAK2 exon 12 have also been described, but a thorough bone marrow study has not been done. We identified 7 PV cases with exon 12 mutations; all had ...

Journal: :Haematologica 2015
Ioanna Triviai Thomas Stübig Birte Niebuhr Kais Hussein Asterios Tsiftsoglou Boris Fehse Carol Stocking Nicolaus Kröger

Primary myelofibrosis is a myeloproliferative neoplasm characterized by bone marrow fibrosis, megakaryocyte atypia, extramedullary hematopoiesis, and transformation to acute myeloid leukemia. To date the stem cell that undergoes the spatial and temporal chain of events during the development of this disease has not been identified. Here we describe a CD133(+) stem cell population that drives th...

Journal: :Maedica 2015
Mihaela Tevet Razvan Ionescu Cornel Dragan Anca Roxana Lupu

BACKGROUND A number of studies showed that the JAK2 V617F mutation increases the thrombotic risk in patients with myeloproliferative disorders (MPN) while others did not reveal this correlation, and it is unknown whether inherited thrombophilia is an additive risk factor in mutated subjects. Our aim was to clarify the contribution of JAK2 V617F to a hypercoagulable state, as well as its interac...

Journal: :Blood 2009
Cécile Saint-Martin Gwendoline Leroy François Delhommeau Gérard Panelatti Sabrina Dupont Chloé James Isabelle Plo Dominique Bordessoule Christine Chomienne André Delannoy Alain Devidas Martine Gardembas-Pain Françoise Isnard Yves Plumelle Olivier Bernard William Vainchenker Albert Najman Christine Bellanné-Chantelot

The JAK2(V617F) mutation does not elucidate the phenotypic variability observed in myeloproliferative neoplasm (MPN) families. A putative tumor suppressor gene, TET2, was recently implicated in MPN and myelodysplastic syndromes through the identification of acquired mutations affecting hematopoietic stem cells. The present study analyzed the TET2 gene in 61 MPN cases from 42 families. Fifteen d...

Journal: :American journal of clinical pathology 2010
Shrimati Shetty Bipin Kulkarni Navin Pai Preeti Mukundan Priyanka Kasatkar Kanjaksha Ghosh

The JAK2(V617F)mutation is recurrent in polycythemia vera and essential thrombocythemia, which are myeloproliferative neoplasms frequently associated with arterial and venous thromboembolism. It has also been reported as a marker for occult myeloproliferative disorder (MPD) in patients with splanchnic venous thrombosis. Limited data are available regarding the prevalence of the JAK2(V617F) muta...

الهی, فاضل, امامی, امیرحسین, تراب, زهرا, موثق پور اکبری, علی اکبر, پوپک, بهزاد, یونسی, محمدرضا,

چکیده سابقه و هدف پلی‌سایتمی‌ورا، یکی از نئوپلاسم‌های میلوپرولیفراتیو BCR-ABL1  منفی می‌باشد که از پروژنیتورهای هماتولوژیک به وجود می‌آید. در حدود 4%-3% بیماران پلی‌سایتمی‌ورا، دارای موتاسیون‌هایی در اگزون 12 ژن JAK2 می‌باشند. با توجه به اهمیت این موتاسیون‌ها در تشخیص بیماران مبتلا به پلی‌سایتمی‌ورا،  مطالعه حاضر انجام گرفت. مواد و روش‌ها در این مطالعه توصیفی ـ تحلیلی، موتاسیون‌های اگزون 12 ژن...

Journal: :Haematologica 2016
Alberto Alvarez-Larrán Arturo Pereira Paola Guglielmelli Juan Carlos Hernández-Boluda Eduardo Arellano-Rodrigo Francisca Ferrer-Marín Alimam Samah Martin Griesshammer Ana Kerguelen Bjorn Andreasson Carmen Burgaleta Jiri Schwarz Valentín García-Gutiérrez Rosa Ayala Pere Barba María Teresa Gómez-Casares Chiara Paoli Beatrice Drexler Sonja Zweegman Mary F McMullin Jan Samuelsson Claire Harrison Francisco Cervantes Alessandro M Vannucchi Carlos Besses

The role of antiplatelet therapy as primary prophylaxis of thrombosis in low-risk essential thrombocythemia has not been studied in randomized clinical trials. We assessed the benefit/risk of low-dose aspirin in 433 patients with low-risk essential thrombocythemia (271 with a CALR mutation, 162 with a JAK2(V617F) mutation) who were on antiplatelet therapy or observation only. After a follow up ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید